Skip to content
Triangle logo TriangleGet started
← Study library

NCT02561273 · REGISTRY CONDITION SEARCH

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2023-12-13

This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new blood vessels necessary for cancer growth. Giving combination chemotherapy with lenalidomide may be a better treatment for peripheral T-cell non-Hodgkin's lymphoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP

→

outcome · POSTED

Number of Participants With Adverse Events Graded According to Common Toxicity Criteria (CTC) (Phase I)

→

outcome · POSTED

Complete Response Rate (Phase II)

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Number of Participants With Adverse Events Graded According to CTC (Phase II)

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression-free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed new diagnosis of stage II, III and IV peripheral T-cell non-Hodgkin's lymphoma not otherwise specified (NOS), anaplastic large cell lymphoma (ALK negative) (ALK positive if IPI 3, 4, or 5), angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma, hepatosplenic gamma delta T-cell lymphoma * Pathology material: hematoxylin and eosin (H\&E) stain and immunohistochemistry (IHC) slides or a representative formalin-fixed paraffin-embedded (FFPE) tissue block along with the pathology report from initial diagnosis, should be sent to be reviewed, and the diagnosis confirmed by Mayo Clinic department (retrospective diagnostic review: treatment may commence prior to the Mayo Clinic review) * No prior therapy with the exception of prior radiation therapy and/or prednisone alone, at the discretion of the investigator based on current diagnosis and clinical condition; this prednisone treatment will not count toward the 6 cycles of treatment given in the study * Expected survival duration of \> 3 months * Karnofsky performance status \> 70 * Absolute neutrophil count (ANC) \> 1000 cells/mm\^3, unless cytopenias due to non-Hodgkin lymphoma (NHL) (i.e., bone marrow involvement or splenomegaly) * Platelet count \> 100,000/uL or \> 75,000/uL if bone marrow (BM) involvement or splenomegaly * Total bilirubin =\< 1.5 x upper normal limit, or =\< 3 x upper normal limit if documented hepatic involvement with lymphoma, or =\< 5 x upper normal limit if history of Gilbert's disease * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x upper normal limit (=\< 5 x upper normal limit if documented hepatic involvement with lymphoma) * Serum creatinine \< 2.0 mg/dL or calculated creatinine clearance (CrCl) \> 45 mL/min (Cockcroft-Gault) * Prothrombin time (PT) or international normalized ratio (INR), and partial thromboplastin time (PTT) =\< 1.5 x upper limit of normal unless patient is receiving anticoagulants; if patient is on warfarin therapy, levels should be within therapeutic range * If currently not on anticoagulation medication, willing and able to take aspirin (81 or 325 mg) daily; if aspirin is contraindicated, the patient may be considered for the study if on therapeutic dose warfarin or low molecular weight heparin; patients unable to take any prophylaxis are not eligible * Patients with measurable disease; patients with non-measurable but evaluable disease may be eligible after discussion with the principal investigator (PI); baseline measurements and evaluations must be obtained within 6 weeks of registration to the study; abnormal positron emission tomography (PET)/computed tomography (CT) scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging * Patients with measurable disease must have at least one objective measurable disease parameter; a clearly defined, bi-dimensionally measurable defect or mass measuring at least 1.5 cm in diameter on the CT portion of a PET/CT or CT scan or magnetic resonance imaging (MRI) (if appropriate) will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can be used as measurable disease provided bi-dimensional measurements are possible * All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program * Women must not be pregnant or breast-feeding * Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program * All females of childbearing potential must have a blood test within 2 weeks prior to registration to rule out pregnancy * Pregnancy testing is not required for post-menopausal or surgically sterilized women * Male and female patients of reproductive potential must agree follow accepted birth control measures * Patient must be able to adhere to the study visit schedule and other protocol requirements * Patients must be willing to give written informed consent, and sign an institutionally approved consent form before performance of any study-related procedure not part of normal medical care as noted above; with the exception of 1 cycle of chemotherapy based on current diagnosis and clinical condition, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * No serious disease or condition that, in the opinion of the investigator, would compromise the patient's ability to participate in the study Exclusion Criteria: * Pregnant or breast feeding females * Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive ( i.e. hepatitis B core antibody positive; quantitative deoxyribonucleic acid \[DNA\] negative) are eligible with appropriate prophylaxis * Major surgery within 2 weeks of study drug administration * Prior malignancies within the past 3 years with exception of adequately treated basal cell, squamous cell skin cancer, or thyroid cancer; carcinoma in situ of the cervix or breast; prostate cancer of Gleason grade 6 or less with stable prostate-specific antigen (PSA) levels * Patients with a diagnosis of other peripheral T-cell lymphoma (PTCL) histologies other than those specified in the inclusion criteria * Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, or antiviral drugs * Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent * Known hypersensitivity to thalidomide or lenalidomide * The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugs * Ejection fraction of \< 45% by either multi gated acquisition scan (MUGA) or echocardiogram (ECHO)
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows: TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care. MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Autologous Hematopoietic Stem Cell Transplantation
    2. Drug: Cyclophosphamide
    3. Drug: Doxorubicin Hydrochloride
    4. Drug: Etoposide
    5. Other: Laboratory Biomarker Analysis
    6. Drug: Lenalidomide
    7. Procedure: Peripheral Blood Stem Cell Transplantation
    8. Drug: Prednisone
    9. Drug: Vincristine Sulfate
    label
    Treatment (combination chemotherapy, lenalidomide)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Undergo autologous stem cell transplant
    name
    Autologous Hematopoietic Stem Cell Transplantation
    other Names
    1. Autologous Stem Cell Transplantation
    type
    PROCEDURE
  2. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  3. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Given IV
    name
    Doxorubicin Hydrochloride
    other Names
    1. 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)
    2. ADM
    3. Adriacin
    4. Adriamycin
    5. Adriamycin Hydrochloride
    6. Adriamycin PFS
    7. Adriamycin RDF
    8. ADRIAMYCIN, HYDROCHLORIDE
    9. Adriamycine
    10. Adriblastina
    11. Adriblastine
    12. Adrimedac
    type
    DRUG
  4. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Given IV
    name
    Etoposide
    other Names
    1. Demethyl Epipodophyllotoxin Ethylidine Glucoside
    2. EPEG
    3. Lastet
    4. Toposar
    5. Vepesid
    6. VP 16-213
    7. VP-16
    8. VP-16-213
    type
    DRUG
  5. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  6. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Given PO
    name
    Lenalidomide
    other Names
    1. CC-5013
    2. CC5013
    3. CDC 501
    4. Revlimid
    type
    DRUG
  7. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Undergo peripheral blood stem cell transplant
    name
    Peripheral Blood Stem Cell Transplantation
    other Names
    1. PBPC transplantation
    2. Peripheral Blood Progenitor Cell Transplantation
    3. Peripheral Stem Cell Support
    4. Peripheral Stem Cell Transplant
    5. Peripheral Stem Cell Transplantation
    type
    PROCEDURE
  8. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Given PO
    name
    Prednisone
    other Names
    1. .delta.1-Cortisone
    2. 1, 2-Dehydrocortisone
    3. Adasone
    4. Cortancyl
    5. Dacortin
    6. DeCortin
    7. Decortisyl
    8. Decorton
    9. Delta 1-Cortisone
    10. Delta-Dome
    11. Deltacortene
    12. Deltacortisone
    type
    DRUG
  9. arm Group Labels
    1. Treatment (combination chemotherapy, lenalidomide)
    description
    Given IV
    name
    Vincristine Sulfate
    other Names
    1. Kyocristine
    2. Leurocristine Sulfate
    3. Leurocristine, sulfate
    4. Oncovin
    5. Vincasar
    6. Vincosid
    7. Vincrex
    8. Vincristine, sulfate
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
54
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    MTD is defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I) within the first cycle of study treatment.
    measure
    Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP
    time Frame
    21 days
  2. description
    Non-hematologic toxicities will be evaluated via the ordinal CTC standard toxicity grading. Hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTC standard toxicity grading. Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized.
    measure
    Number of Participants With Adverse Events Graded According to Common Toxicity Criteria (CTC) (Phase I)
    time Frame
    Up to 6 cycles of treatment (approximately 5 months)
  3. description
    A success is defined to be an objective status of CR after completion of 6 cycles of treatment. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. A 95% confidence interval for the true overall CR rate will be calculated according to the method of Duffy and Santner.
    measure
    Complete Response Rate (Phase II)
    time Frame
    Up to the completion of course 6 (18 weeks)
  4. description
    The ORR will be estimated by the total number of patients who achieve a PR or CR at the end of six cycles of treatment divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true ORR will be calculated.
    measure
    Overall Response Rate
    time Frame
    Up to the completion of course 6 (18 weeks)
secondary Outcomes
  1. description
    The toxicity profile will be further assessed based on phase II patients. Overall toxicity incidence of maximum tolerated dose level of the Intent to treat (ITT) group of subjects is summarized. 39 subjects were dosed with 10 mg dose of Lenalidamide as the ITT group.
    measure
    Number of Participants With Adverse Events Graded According to CTC (Phase II)
    time Frame
    Up to 1 year
  2. description
    The distribution of overall survival will be estimated using the method of Kaplan-Meier.
    measure
    Overall Survival
    time Frame
    Time from registration to death due to any cause, assessed up to 1 year
  3. description
    The distribution of PFS will be estimated using the method of Kaplan-Meier. The PFS rate at 2 years will be estimated. A 2-year PFS rate of 60% will be considered of interest.
    measure
    Progression-free Survival
    time Frame
    Time from registration to progression or death due to any cause, assessed up to 2 years
Full study description
brief Summary
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new blood vessels necessary for cancer growth. Giving combination chemotherapy with lenalidomide may be a better treatment for peripheral T-cell non-Hodgkin's lymphoma.
detailed Description
PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin \[doxorubicin hydrochloride\], etoposide, vincristine \[vincristine sulfate\] and prednisone) in patients with newly diagnosed stage II, III and IV peripheral T-cell lymphoma not otherwise specified (NOS), anaplastic large cell lymphoma (anaplastic lymphoma receptor tyrosine kinase \[ALK\] negative) (ALK positive if International Prognostic Index \[IPI\] 3, 4, or 5), angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma or hepatosplenic gamma delta T-cell lymphoma. II. To establish the maximum tolerated dose of lenalidomide in combination with CHOEP chemotherapy. (Phase I) III. To assess the efficacy (complete response rate) of this combination. (Phase II) SECONDARY OBJECTIVES: I. To evaluate overall response rate (complete response \[CR\] + partial response \[PR\]) of the combination of lenalidomide and CHOEP chemotherapy. II. To evaluate the safety and tolerability of the regimen. III. To assess the 2 year progression free survival (PFS) and overall survival (OS) using this regimen. OUTLINE: This is a phase I, dose-escalation study of lenalidomide, followed by a phase II study. Patients receive cyclophosphamide intravenously (IV), doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone orally (PO) on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows: TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care. MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-a484341c4373ac3c614f
      requested nct id
      NCT02561273
      primary nct id
      NCT02561273
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      bfc9dacf6aa77990b69ab0e4645783268fef79d46405a0c9b211195c036e03e9
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-a484341c4373ac3c614f
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02561273
      occurrences
      1. context exact
        NCT02561273
        end
        11
        exact text
        NCT02561273
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/55/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      2fcd713138ea302a26d39984a120296615817060b00c7fdd5c3191d1549917d7

    Preserved source evidence · Not medical advice